Rodman & Renshaw analyst Brandon Folkes initiates coverage on Cormedix (NASDAQ:CRMD) with a Buy rating and announces Price Target of $13.
- Headlines
- Rodman & Renshaw Initiates Coverage On Cormedix With Buy Rating, Announces Price Target of $13
Rodman & Renshaw Initiates Coverage On Cormedix With Buy Rating, Announces Price Target of $13
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.
Related Stocks Related Stocks
Symbol Mini Chart Price
Log In for the Full List
Latest
07:31
Nikkei/Yen Futures opened up 390 points at the Singapore Exchange, reporting 39350 points.
07:30
In December, Australia's The Pacific Banks Leading Index fell by 0.02% month-on-month.
07:29
Morgan Stanley has upgraded GigaDevice Semiconductor Inc. to Neutral rating with a Target Price of 130 yuan.
GigaDevice Semiconductor Inc.-0.68%